Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 1st GBHI-Conference – Conference Report now available 3rd GBHI conference – program is online Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Hypothalamic Dermal irritation Pharmacodynamic studies PASS Statistical services Subcontractor qualification Phase I Unit Recruitment rates Consultancy Charcoal Degeneration Protocol development GCP training Clinical study Patients Edema Uveitis Cough Ophthalmological trials SocraTec C&S In vitro in vivo correlation CDISC FDA Metered dose inhaler Transdermal therapeutic system MCID Creativity Early phase HRT TTS Network CRA Adrenocortical Phase II Intensive assessment station CRF Drug Food Interaction Elpro Quality Assurance Drug Drug Interaction MDI Immunogenicity Informed Consent Procedure Dry powder inhaler Spacious archive GLP Auditing Statistical Analysis Plan Experience Pulse oximetry plethysmography CDASH Bioequivalence SOP based OTC Authorities EMA Protocol Scientific advice COPD Dose linearity IMPD DDI HPA axis Legal representative Postmenopausal women Sensitisation trials DFI SDV Biopharmaceutics Clinical Monitoring CDM First in human Pituitary AGAH Phase III Source Data Verification Data Validation Plan Statistical programming Sample size estimation Anaesthesiologist Centralised procedure Axis Allergy Clinical trials Pharmacokintetics Xerostomia Pharmacokinetics Phase IV Biopharmaceutical Glaucoma Investigators brochure Biosimilars Lung Absorption Clinical pharmacology unit IEC Central surveillance system Patch adhesion Endpoint Cardiovascular surveillance Training Paediatricians CRO Healthy subjects Phase I Patient recruitment Local tolerability Dry eye Children Oncological patients Absorption windows Macular Bioavailability Copyright Asthma Sore throat Safety DPI Sequential designs Ophthalmologist Ophthalmology Phase IIb trials Pharmacology Oncologic network Scientific expertise Ovulation inhibition Thuringia ANVISA FIM Design development Referral system ADAM Rhine Main area Database Monitoring Patch NIS Clinical development program Female adolescents SAS Product development Quality Management System PAES DUS Oncology Slit lamp microscopy Non interventional Highly variable drugs Feasibility HTA Biometrics Audit WinNonlin Pilot study Life cycle management MMM Efficacy Phase IIa trials Steady state IB Inhalatives Expert Common cold Project Management ICF Legal Information Eye disease Hormone replacement therapy IVIVC Post authorisation Good Clinical Practice Contraception Quality Data management Ocular tolerability Data Management Plan CDSIC US CFR 21 Part 11 Gynaecological trials US FDA Standardisation Competence GCP Standard operating procedure Inspection Pragmatism  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page